Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Pruritus Therapeutics
... CAGR of 4.6% over the analysis period 2024-2030. Corticosteroids, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$4.7 Billion by the end of the analysis period. ... Read More
-
Protein Therapeutics
... CAGR of 5.8% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$284.7 Billion by the end of the analysis ... Read More
-
Small Molecule Drug Discovery
... 2030, growing at a CAGR of 8.4% over the analysis period 2024-2030. Oncology Therapeutic Area, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$38.9 Billion by ... Read More
-
Systemic Psoriasis Therapeutics
... at a CAGR of 8.1% over the analysis period 2024-2030. TNF Inhibitors, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$18.5 Billion by the end of ... Read More
-
Amyotrophic Lateral Sclerosis
... at a CAGR of 19.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$345.9 Million While China is Forecast to Grow at 18.4% CAGR The Amyotrophic Lateral Sclerosis market in the U.S. ... Read More
-
Colorectal Cancer Therapeutics
... at a CAGR of 6.5% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$14.9 Billion by the end of ... Read More
-
Hemophilia Drugs
... CAGR of 5.5% over the analysis period 2024-2030. Hemophilia A, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$21.3 Billion by the end of the analysis ... Read More
-
Infertility Drugs
... CAGR of 5.2% over the analysis period 2024-2030. Hormone-Based Therapy, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$5.3 Billion by the end of the analysis ... Read More
-
Kaposi Sarcoma
... CAGR of 3.2% over the analysis period 2024-2030. HAART, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$101.5 Million by the end of the analysis period. ... Read More
-
MRSA Drugs
... CAGR of 4.5% over the analysis period 2024-2030. Glycopeptides & Lipoglycopeptides, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$726.5 Million by the end of the ... Read More
-
Non-Hodgkin Lymphoma Therapeutics
... at a CAGR of 7.0% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$10.1 Billion by the end of the ... Read More
-
Critical Care Therapeutics
... at a CAGR of 5.7% over the analysis period 2024-2030. Albumin, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$3.7 Billion by the end of the ... Read More
-
Cushing`s Syndrome Diagnostics and Treatment
... Million by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Treatment, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$473.9 Million by ... Read More
-
Gastroparesis Drugs
... CAGR of 4.8% over the analysis period 2024-2030. Idiopathic Gastroparesis, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$4.3 Billion by the end of the analysis ... Read More
-
Gynecological Cancer Drugs
... at a CAGR of 5.1% over the analysis period 2024-2030. Cervical Cancer, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$10.3 Billion by the end of ... Read More
-
Hereditary Angioedema
... CAGR of 7.7% over the analysis period 2024-2030. C1 Esterase Inhibitors, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$2.5 Billion by the end of the ... Read More
-
Periodontal Therapeutics
... CAGR of 8.6% over the analysis period 2024-2030. Systemic Antibiotics, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$623.3 Million by the end of the analysis ... Read More
-
Label-Free Detection
... CAGR of 7.4% over the analysis period 2024-2030. Label-Free Detection Instruments, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$518.8 Million by the end of the ... Read More
-
Lupus Therapeutics
... CAGR of 8.7% over the analysis period 2024-2030. Anti-Inflammatory Drugs, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$2.7 Billion by the end of the analysis ... Read More
-
Thin Film Drug Manufacturing
... 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. Oral Thin Film, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$9.9 Billion by ... Read More
-
Desmopressin
... 5.6% over the analysis period 2024-2030. Injectable Solution, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$866.1 Million by the end of the analysis period. Growth ... Read More
-
Bovine Respiratory Disease Treatment
... 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Vaccines, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$1.4 Billion by the end ... Read More
-
Hypercalcemia Treatment
... CAGR of 9.3% over the analysis period 2024-2030. Bisphosphonates, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$28.0 Billion by the end of the analysis period. ... Read More
-
Idiopathic Pulmonary Fibrosis
... at a CAGR of 5.7% over the analysis period 2024-2030. PIRFENIDONE, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$4.8 Billion by the end of the ... Read More
-
Krabbe Disease Treatment
... at a CAGR of 6.2% over the analysis period 2024-2030. Anticonvulsants, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$823.5 Million by the end of the ... Read More
Research Assistance
